BBIO (BridgeBio Pharma) Days Payable : 642.16 (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Days Payable?

BridgeBio Pharma's average Accounts Payable for the three months ended in Mar. 2025 was $18.6 Mil. BridgeBio Pharma's Cost of Goods Sold for the three months ended in Mar. 2025 was $2.6 Mil. Hence, BridgeBio Pharma's Days Payable for the three months ended in Mar. 2025 was 642.16.

The historical rank and industry rank for BridgeBio Pharma's Days Payable or its related term are showing as below:

BBIO' s Days Payable Range Over the Past 10 Years
Min: 904.76 Med: 1245.83 Max: 1657.35
Current: 904.76

During the past 8 years, BridgeBio Pharma's highest Days Payable was 1657.35. The lowest was 904.76. And the median was 1245.83.

BBIO's Days Payable is ranked better than
84.56% of 706 companies
in the Biotechnology industry
Industry Median: 121.27 vs BBIO: 904.76

BridgeBio Pharma's Days Payable declined from Mar. 2024 (1,173.66) to Mar. 2025 (642.16). It may suggest that BridgeBio Pharma accelerated paying its suppliers.

BridgeBio Pharma Days Payable Historical Data

The historical data trend for BridgeBio Pharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Days Payable Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

1,220.71

1,245.83

1,657.35

954.05

BridgeBio Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Days Payable	Get a 7-Day Free Trial															1,173.66	1,743.67	2,402.48	503.12	642.16

Competitive Comparison of BridgeBio Pharma's Days Payable

For the Biotechnology subindustry, BridgeBio Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Pharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Days Payable distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Days Payable falls into.

Save Embed

;

Save Embed

;

BridgeBio Pharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

BridgeBio Pharma's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (10.655	+	9.618)	/	2 )	/	3.878	*	365
=	10.1365					/	3.878	*	365
=	954.05

BridgeBio Pharma's Days Payable for the quarter that ended in Mar. 2025 is calculated as:

	Days Payable (Q: Mar. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2024 )	+	Accounts Payable (Q: Mar. 2025 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2025 )	*	Days in Period
=	( (9.618	+	27.525)	/	2 )	/	2.639	*	365 / 4
=	18.5715					/	2.639	*	365 / 4
=	642.16

BridgeBio Pharma Days Payable Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (NAS:BBIO) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

1BBIO:Italy 2CL:Germany

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Executives

Neil Kumar	director, officer: See Remarks	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Kkr Genetic Disorder L.p.	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Andrew Lo	director	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Andrea Ellis	director	C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
Hannah Valantine	director	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Brian C Stephenson	officer: See Remarks	3160 PORTER DR, STE 250, PALO ALTO CA 94304
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Randal W Scott	director	171 MAIN STREET #225, LOS ALTOS CA 94022
Frank Mccormick	officer: Chairman of Oncology	C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Douglas A. Dachille	director	175 WATER STREET, NEW YORK NY 10038
Ronald J Daniels	director	C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901
Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
James C Momtazee	director	2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Brent L Saunders	director	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033